Understanding Immunity to the COVID-19 Vaccines

Overview

The purpose of this study is to test over time immunity to the COVID-19 vaccines. Adults who are receiving COVID-19 vaccines will be invited to participate.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 2023

Interventions

  • Other: No intervention
    • No intervention

Arms, Groups and Cohorts

  • Participants
    • Adults who are receiving a COVID-19 vaccine

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of participants with immunity to COVID-19 vaccines over time
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • Adults who are receiving a COVID-19 vaccine Exclusion Criteria:

  • Patients with special risks attendant to venipuncture

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Stanford University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kari Christine Nadeau, MD, PhD, Professor of Medicine – Stanford University
  • Overall Official(s)
    • Kari Nadeau, MD, PhD, Principal Investigator, Stanford University
  • Overall Contact(s)
    • SNP Center Inquiry, (650) 521-7237, snpcenterallergy_inquiry@stanford.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.